Global Epilepsy Drugs Market Size, Insights, Drivers, Opportunities, By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics, Others), By Region, Growth, Trends and Forecast from 2019 to 2027
Global Epilepsy Drugs Market Size, Insights, Drivers, Opportunities, By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics, Others), By Region, Growth, Trends and Forecast from 2019 to 2027
Historic years: 2015 to 2017 Base Year: 2018 Forecast Years: 2019 to 2027
Number of pages: 100 Category: Healthcare Report Id: MISHC5005
Market Insights
The global epilepsy drugs market was valued at USD 4.67 billion in 2018 and is estimated to reach a value of USD 7.41 billion in 2027. The market is analyzed to rise at a CAGR of 5.26% over the forecast period of 2019 to 2027. The rise in the number of product launches in the market such as Ganaxolone, Perampanel, USL261, and YKP3089 has driven the demand for the epilepsy drugs market. The rising number of children and adults diagnosed with epilepsy along with its prevalence for the treatment using different generation products has anticipated the growth for the market.Global epilepsy drugs market size by region, 2018 (USD Billion)
Primary and secondary market researchers have identified UCB Pharma Ltd., Valeant Abbott Laboratories, Inc. Pharmaceuticals International, Inc., Sanofi S.A, Pfizer, Inc. and Eisai Co., Ltd., Johnson & Johnson, as the key players in the global epilepsy drugs scenario. However, upon analysis of this segment, factors like company revenue and industry trends towards selecting a particular group and penetration of the epilepsy drugs manufacturers are of pivotal importance.
The constant product innovations from the manufacturers in the market have been driving the growth of the industry over the forecast period. The rise in the use of products for epilepsy treatments in the market is fueling the demand of the consumers towards the quality products. The market is also benefited by the demands of the products for the infants in the world. The rise in the prevalence of disease along with the urbanization leading to the hectic lifestyle has increased the demand for the products in the market.
Treatment Insights
Second generation treatment is estimated to be the largest segment holding a share of about 36% share in the market. In 2018, the second generation treatment market was estimated to be USD 1.70 billion and is expected to reach USD 2.67 billion in 2027 with a CAGR of 5.15% over the period of 2019 to 2027. Second generation treatment continues the dominance due to its prescription from the physicians having an extra safety and tolerability for its product. The third generation treatment market is have a fastest growth in the market due to its high prevalence and adoption of such products in the market over the forecast period.Global epilepsy drugs market value share by treatment, 2027 (%)
Regional Insights
As of 2018, North America accounts for the largest share in the epilepsy drugs market, with a share of over 38% of the global market. The rise in the consumption of products due to favorable initiatives from government along with the rise in the disposable income of the consumers in the developed countries such as U.S. and Canada provide the product, a reasonable demand from the global market. U.S. dominates the global market for the growth of epilepsy drugs due to the rise in product launches and extensive research and efforts for development in the market. The report is a thorough market study which includes top companies, their annual presentations, industry publications, press releases and their drivers, opportunities, trends and the product understanding through different modes (Treatment, and Regional analysis) with growth factors and future expectancies in the epilepsy drugs market.Research Methodology
The following report consists of market analysis including both primary and secondary research. Primary research comprises the interaction between manufacturers, industry experts and channel partners, while the secondary research presents an analytical interpretation of relevant publications which contains details like proprietary databases, purchased database, company annual reports, and financial reports. For single, team and corporate user license, we will provide 15% free customization of the report. However, alternatively, if you are looking for additional data or insight related to the scope of the report, you may purchase the "Customized Research License". Please put an enquiry for the pricing details.Segments covered in the report
Treatment Outlook- First Generation Anti-epileptics
- Second Generation Anti-epileptics
- Third Generation Anti-epileptics
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Asia Pacific
- China
- Japan
- India
- Central & South America
- Brazil
- Middle East & Africa
- All market trends, drivers and opportunities
- Analyzing the regional market for the growth factors, estimated analysis and its penetration to the global market
- The complete analysis of the parent market
- Top changes in the market dynamics
- Market opportunity assessment
- Detailed market segmentation and detailed analysis with the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Analysis of market share and developments
- Detailed company profiling of leading companies
- Opportunities to newer markets in global and regional markets
- Analysis of the trajectory line of the market
- Measures to consider for strengthening epilepsy drugs products in the market